compname announces quarterly dividend, provides dividend per common share of $0.26.
compname posts quarterly guidance.
qtrly human health sales up 2%.
qtrly primary and secondary pharmaceutical products sales of over $2 billion, an increase of over 30% year-over-year.
qtrly net sales of $8.9 billion decreased 1% to $8,9 billion.
company expects net revenue growth of about 5%.
quarterly outlook includes increased u.s. share repurchases and a repurchase program to acquire approximately $40 million of common stock and a few additional stock buybacks.
compname reports fourth quarter and full year 2021 results; reaffirms outlook for keytruda and lmc.
q4 sales $482 million versus refinitiv ibes estimate of $514.2 million.
q4 sales $311 million versus refinitiv ibes estimate of $266.6 million.
compname reports quarterly results, as well as provides strong results from results of clinical trials, including its recent launch of new pd-l1 testing in non-small-cell lung cancer.
sees half of new patient volumes were tested at or near 100 percent for q4, and a full second quarter of 2021.
q1 same store sales up 10%.
qtrly net sales $172 million, an increase of 29% compared to q4 2021.
compname reports third quarter results and announces second-line non-small-cell lung cancer market approval in more than 50 markets.
expect a meaningful contribution in 2017 from second-line lung as many countries come online.
